Three lenses go head-to-head

Article

The implantation of multifocal and accommodative intraocular lenses (IOLs) can offer adequate near and far vision in addition to high levels of patient satisfaction.

The implantation of multifocal and accommodative intraocular lenses (IOLs) can offer adequate near and far vision in addition to high levels of patient satisfaction, according to Georgio Marchini and colleagues from the University of Verona, Italy.

The researchers enrolled 120 eyes (60 patients) to undergo bilateral phacoemulsification and split the patients into three groups of 40 eyes. Group 1 received the diffractive ReSTOR (Alcon), Group 2 received the refractive ReZoom (AMO) and Group 3 received the accommodative Crystalens AT-45 (Eyeonics).

The results demonstrated that there were no statistical differences in uncorrected distance visual acuity (UCDVA) and best corrected distance visual acuity (BCDVA) among the three groups. Those in the ReStor group did, however, achieve better uncorrected near visual acuity (UCNVA) and best distance corrected near visual acuity (BDCNVA). Bigger accommodative amplitude and better contrast sensitivity, with and without glare, was noted in the Crystalens group.

It was concluded that, although each lens provides adequate visual acuity, the ReStor lens performs best in near vision, the Crystalens and ReZoom offer more useful accommodative amplitude and the Crystalens also offers better contrast sensitivity.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.